Towa Pharmaceutical Co., Ltd.
Supplementary Financial Presentation Materials
Revenue 142,254 million yen (YoY +9.0%), Operating Income 12,745 million yen (YoY +22.0%), Ordinary Income 10,093 million yen, Net Income Attributable to Owners of Parent for the interim period 6,866 million yen. Achieved the first-half plan largely, supported by trends at Towa Pharmaceutical and Sansho Pharmaceutical. Will closely monitor developments in Europe and the U.S. in the second half. Increases in R&D expenses and SG&A impacted results.
Key Figures
- Revenue: 142,254 million yen
- Operating Income: 12,745 million yen
- Ordinary Income: 10,093 million yen
AI要約
Summary of Results
For the second quarter of the fiscal year ending March 2027, consolidated revenue increased year-on-year, and despite increases in SG&A and R&D expenses, operating income rose significantly. Contributions from overseas segments and improved profitability in domestic segments supported near achievement of the first-half plan.
Outlook and Points to Note
The second half is likely to be sensitive to market trends in Europe and the United States, with the sales progress of the new application business and the status of license revenue being particularly important. The impact of non-cash items such as goodwill amortization continues, and attention should be paid to overall profit levels.
Revenue Trend
Operating Income Trend
Gross Margin / SG&A Ratio Analysis
Comparison of Guidance and Actuals
Towa Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
